Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Health Department in Utah Bans Gardasil; The CBCD Urges the CDC to Re-examine the Benefits of the HPV Vaccine
  • USA - English


News provided by

Center for the Biology of Chronic Disease (CBCD)

Dec 09, 2013, 03:00 ET

Share this article

Share toX

Share this article

Share toX


Rochester, NY (PRWEB) December 09, 2013 -- Utah’s Southwest Health Department has banned Gardasil, “citing low demand, high costs - and questioning the benefits (1).” In contrast, many health departments and doctors across America continue to recommend Gardasil as prevention against HPV infection. These state health departments and doctors rely on government agencies like the CDC for their information. Utah is not alone. As it turns out, the health ministries of Japan and Israel have both raised serious concerns regarding the HPV vaccine.

'The science wasn’t good... We had physicians in our community arguing that we not make it available. HPV is absolutely a risk for cervical cancer, but it’s not the only risk.' - Dr. Blodgett, Utah South West Health Dept. (1)

Post this

In June 2013, the Drugs.com website reported that the Japanese government “has withdrawn its recommendation for vaccination after receiving hundreds of side effects reports of long-term pain and numbness, among other things (3).” Criticism of the Gardasil vaccine has also come from Israel. Dr. Uzi Beller, an international authority on gynecological cancers who treats patients on a daily basis, came out publicly against vaccinating 65,000, 14-year old girls in Israel with Gardasil, according to an article published in The Jerusalem Post on September 21, 2013 (4).

Dr. Beller voiced his criticism of Gardasil vaccination at “a meeting in Tel Aviv … (with) 40 leading experts on gynecology, oncology, women’s health, vaccines and other specialties (4).”

When describing his opposition to Gardasil vaccination, Dr. Beller said, “I am not at all against vaccines. I just underwent the oral polio vaccination as the Health Ministry instructed medical institutions to give the two drops to every doctor who is in direct contact with patients. But, HPV is different from all other vaccines. It is not a vaccination against cervical cancer but against a virus that in some cases causes a premalignant condition, and in a small number of cases, a malignancy (4).”

“…in an interview with The Jerusalem Post in his office, (Dr. Beller) noted that the…pharmaceutical companies that manufacture the vaccine have been extremely aggressive in their lobbying and marketing; the vaccines are worth billions of dollars to them. At the same time, he said, many medical professionals who advocate vaccination have been pushing a “populistic campaign without being familiar with the issue (4).”

Dr. Beller continued by saying, “I would be happy to see a solution to this disease. Unlike mammography, there is no organized health fund screening for cervical cancer required, even though Pap smear testing has been shown to be worthwhile in early detection. I want to see fundamental studies proving efficacy, and they do not exist. The vaccines were tested on mostly white women attending colleges and university – mostly from developed countries and healthy. The data were based on a relatively short-term follow-up period. What is known does not yet justify widespread vaccination of healthy girls (4).”

Utah’s director of the Southwest Health Department agrees, noting that regarding Gardasil, “The science wasn’t good... We had physicians in our community arguing that we not make it available. HPV is absolutely a risk for cervical cancer, but it’s not the only risk (1).” The article went on to quote Dr. Blodgett saying that, “Weighed against the vaccine’s risks, ‘the public isn’t buying it. It’s eroding public trust in immunization programs.’"

“Health experts from Japan and Israel, two of America’s leading allies, have voiced concerns about Gardasil. Now one of America’s state health officials is speaking up against the vaccine. Government health authorities in the CDC should heed these concerns as well.” –Greg Bennett, CBCD

The CBCD believes that health officials and doctors across America should re-examine the benefits of Gardasil.

To discuss this issue with a CBCD representative, journalists can contact The Center at info(at)cbcd(dot)net, or by calling 585-250-9999.

References:
(1) Utah health official bans Gardasil, stirring controversy. Published on December 6, 2013.
        http://www.sltrib.com/sltrib/news/57224192-78/vaccine-health-percent-utah.html.csp

(2)    Should Your Child Get the HPV Vaccine? Published on January 25, 2011.
        http://children.webmd.com/vaccines/features/should-your-child-get-hpv-vaccine

(3)    Citing Side Effects, Japan Pulls Recommendations For HPV Vaccines. Published in June 2013.
        http://www.drugs.com/news/citing-japan-pulls-recommendations-hpv-vaccines-45158.html

(4) HPV: To vaccinate or not to vaccinate. Published on September 21, 2013.
        http://www.jpost.com/Health-and-Science/HPV-To-vaccinate-or-not-to-vaccinate-326711

(5) FDA Rejects Gardasil for Older Women. Published on April 7, 2011.
        http://www.medpagetoday.com/OBGYN/STDs/25776

The CBCD is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments.

The CBCD published the “Purple” book by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between foreign DNA and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

Hanan Polansky, Center for the Biology of Chronic Disease (CBCD), +1 (585) 250-9999, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.